Comorbidity of type 2 diabetes mellitus and diffused non-toxic goiter: laboratory data
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2021.4.12554Keywords:
type 2 diabetes mellitus, diffuse non-toxic goiter, comorbidity, laboratory dataAbstract
Summary. The prevalence of type 2 diabetes and diffuse non-toxic goiter increases worldwide. It has been reported that patients with impaired glucose metabolism have larger thyroid volumes. The researchers have increasingly focused on studying the relationship between insulin resistance and abnormal thyroid function and morphology.
The aim of the study – to evaluate laboratory data in patients with comorbidity of type 2 diabetes mellitus and diffuse non-toxic goiter and identify possible markers of their comorbid course.
Materials and Methods. The study included medical records of 541 patients. Two experimental groups were formed: 40 patients with diffuse non-toxic goiter and type 2 diabetes mellitus and 501 patients with type 2 diabetes only. Each patient had ultrasound examination of thyroid gland. The size of thyroid gland was calculated by the Bruno method. Data of lipid profile, general blood analysis, level of insulin, glucose, biochemical blood analysis, thyroid hormones (TSH, T4) were defined. Statistical analysis was performed by calculating the median (Me), lower (Lq) and upper (Uq) quartiles, Mann-Whitney U-test.
Results. The average age of patients was 56 years. General blood analysis had significantly higher ESR levels by 63.6 % in the group of T2D + diffuse non-toxic goiter in comparison with T2D. Significantly higher levels of HbA1c by 7.4 %, non-HDL-C by 3.57 % in the group T2D + diffuse non-toxic goiter in comparison with T2D.
Conclusions. Patients with combined type 2 diabetes mellitus and diffuse non-toxic goiter have significantly higher levels of ESR, HbA1c, and progressive dyslipidemia due to non-HDL-C, compared with patients with type 2 diabetes mellitus only. There is a tendency to increase total and residual cholesterol in the group of T2D + diffuse non-toxic goiter compared with T2D.
References
World Health Organization. Goitre as a Determinant of the Prevalence and Severity of Iodine Deficiency Disorders in Populations. Geneva, Switzerland: World Health Organization. 2014.
Hetzel BS. The story of iodine deficiency: an international challenge in nutrition. Oxford and New Delhi: Oxford University Press. 1989.
M. Andersson, B. Takkouche, I. Egli. Iodine Status Worldwide, WHO Global Database on Iodine Deficiency: Department of Nutrition for Health and Development Geneva, Switzerland: World Health Organization. 2004
Mesele M, Degu G, Gebrehiwot H. Prevalence and associated factors of goiter among rural children aged 6-12 years old in Northwest Ethiopia, cross-sectional study. BMC Public Health. 2014;14: 130.
Anusha A, Gopalakrishnan S, Savitha A. Evaluation of Goitre and its sociodemographic risk factors among rural school children of Kancheepuram, Tamil Nadu, India. J Clin Diagn Res. 2018;12(6): 10-4.
Malboosbaf R, Hosseinpanah F, Mojarrad M. Relationship between goiter and gender: a systematic review and meta-analysis. Int J Basic Clin Endocrinol. 2013;43: 539.
Cho YA, Kim J. Dietary factors affecting thyroid cancer risk: A meta-analysis. Nutr Cancer. 2015;67(5): 811-7.
Han C, He X, Xia X, Li Y, Shi X, Shan Z, et al. Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(8): e0135233.
Smithson MJ. Screening for thyroid dysfunction in a community population of diabetic patients. Diabet Med. 1998;15(2): 148-50.
Al-Geffari M, Ahmad NA, Al-Sharqawi AH, Youssef AM, Alnaqeb D, Al-Rubeaan K. Risk factors for thyroid dysfunction among type 2 diabetic patients in a highly diabetes mellitus prevalent society. Int J Endocrinol. 2013;2013: 417920.
American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1): S103-S23.
WHO/UNICEF/ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for programme managers 3rd ed. Geneva: World Health Organization. 2007. Available from: http://whqlibdoc.who.int/publications/2007/9789241595827_eng.pdf
Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound (author's transl). Dtsch Med Wochenschr. 1981;106(41): 1338-40.
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1): 57-63.
Tang Y, Yan T, Wang G, et al. Correlation between insulin resistance and thyroid nodule in type 2 diabetes mellitus. International Journal of Endocrinology. 2017;2017: 1617458
Gebremichael G, Demena M, Egata G, Gebremichael B. Prevalence of Goiter and Associated Factors Among Adolescents in Gazgibla District, Northeast Ethiopia. Glob Adv Health Med. 2020;9: 2164956120923624.
Heidari Z, Mashhadi MA, Nosratzehi S. Insulin resistance in patients with benign thyroid nodules. Arch Iran Med. 2015;18(9): 572-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Bulletin of Medical and Biological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
